However, results from the phase 2 clinical trial led by Le et al., to evaluate PD1 checkpoint blockade with Pembrolizumab in treatment of refractory solid tumors (colorectal and non-colorectal cancers) with MSI-H tumors, demonstrated that in this subset of pancreatic cancer patients, the administration of PD1 therapy resulted in durable responses in patients with 24-month progression-free survival (PFS) rate of 53% and 24-month OS rate of 64% [55]. This evidence concerns the gene PDCD1 and colorectal cancer.